Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly).
Under the license agreement, Aclaris granted Lilly non-exclusive rights under certain patents and patent applications that Aclaris exclusively licenses from The Trustees of Columbia University in the City of New York, for the use of baricitinib, Lilly’s JAK inhibitor, to treat alopecia areata (AA). The agreement includes an upfront payment, regulatory and commercial milestones, and royalties.
https://finance.yahoo.com/news/aclaris-therapeutics-announces-patent-license-110000101.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.